0001415889-23-013903.txt : 20231003
0001415889-23-013903.hdr.sgml : 20231003
20231003170058
ACCESSION NUMBER: 0001415889-23-013903
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230929
FILED AS OF DATE: 20231003
DATE AS OF CHANGE: 20231003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boudes Pol F
CENTRAL INDEX KEY: 0001454771
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33357
FILM NUMBER: 231305062
MAIL ADDRESS:
STREET 1: C/O CYMABAY THERAPEUTICS, INC.
STREET 2: 7575 GATEWAY BLVD., SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc.
CENTRAL INDEX KEY: 0001006281
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 650643773
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 UNIVERSITY PLAZA
STREET 2: SUITE 100
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
BUSINESS PHONE: 201-696-9345
MAIL ADDRESS:
STREET 1: 2 UNIVERSITY PLAZA
STREET 2: SUITE 100
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
FORMER COMPANY:
FORMER CONFORMED NAME: ORTHODONTIX INC
DATE OF NAME CHANGE: 19980422
FORMER COMPANY:
FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP
DATE OF NAME CHANGE: 19960124
4
1
form4-10032023_051035.xml
X0508
4
2023-09-29
0001006281
Protalix BioTherapeutics, Inc.
PLX
0001454771
Boudes Pol F
C/O PROTALIX BIOTHERAPEUTICS, INC.
2 SNUNIT STREET SCIENCE PARK, POB 455
CARMIEL
L3
2161401
ISRAEL
true
false
false
false
0
Stock Options (Right to Buy)
1.66
2023-09-29
4
A
0
61676
0
A
2033-09-29
Common Stock
61676
61676
D
The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.
/s/ Eyal Rubin, Attorney-in-Fact
2023-10-03